New office to help integrate Actavis into Watson

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.



Watson announced the formation of the global integration management office, which will report directly to president and CEO Paul Bisaro and focus on integrating the Zug, Switzerland-based generic drug maker, which Watson announced it would acquire last month.



Marc Lehnen, a partner with consulting firm McKinsey & Co., has been hired to lead the office in the newly created position of SVP global integration management, a position he will assume on July 1.



"Watson is committed to integrating the combined assets of our company and Actavis as rapidly and as seamlessly as possible to recognize the combined potential of the global organization and to implement appropriate planning and execution processes to capitalize on the potential synergies that will result from this combination," Bisaro said.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.